Product Description
Floxuridine (FUDR) is a pyrimidine analogue used as an antineoplastic agent, usually as a continuous hepatic arterial infusion to treat hepatic metastases from colon cancer. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Floxuridine)
Mechanisms of Action: DNA Synthesis Inhibitor,TS Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral,Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Italy | United States
Approved Indications: None
Known Adverse Events: None
Company: Jazz
Company Location: DUBLIN L2 4
Company CEO: Bruce C. Cozadd
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
LY01616/CT-CHN-101 | P2 |
Enrolling by invitation |
Oncology Solid Tumor Unspecified |
2024-08-31 |
57% |